Novo’s Wegovy Shows Stronger Weight-Loss Effects in Women Than Men: Study

Novo Nordisk’s blockbuster obesity treatment Wegovy (semaglutide) induced greater weight loss in women than in men with a common type of heart failure, according to research presented Sunday at the American Diabetes Association’s 2024 Scientific Sessions and published in the Journal of the American College of Cardiology.